Literature DB >> 29383580

Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.

Essa Hariri1, Anthony Mansour2, Andrew El Alam2, Yazan Daaboul3, Serge Korjian4, Sola Aoun Bahous5,6.   

Abstract

Sickle cell nephropathy is a major complication of sickle cell disease. It manifests in different forms, including glomerulopathy, proteinuria, hematuria, and tubular defects, and frequently results in end-stage renal disease (ESRD). Different pathophysiologic mechanisms have been proposed to explain the development of nephropathy in SCD, where hemolysis and vascular occlusion are the main contributors in the manifestations of this disease. Markers of renal injury, such as proteinuria and tubular dysfunction, have been associated with outcomes among patients with sickle cell nephropathy and provide means for early detection of nephropathy and screening prior to progression to renal failure. In small-sized clinical trials, hydroxyurea has demonstrated to be effective in slowing the progression to ESRD. Dialysis and renal transplantation represent the last resort for patients with sickle cell nephropathy. Nevertheless, despite the availability of diagnostic and therapeutic strategies, sickle cell nephropathy remains a challenging and under-recognized complication for patients with sickle cell disease.

Entities:  

Keywords:  Hemolysis; Hydroxyurea; Proteinuria; Sickle cell disease; Sickle cell nephropathy; Tubular dysfunction

Mesh:

Substances:

Year:  2018        PMID: 29383580     DOI: 10.1007/s11255-018-1803-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  83 in total

1.  Biomarkers for early detection of sickle nephropathy.

Authors:  Nambirajan Sundaram; Michael Bennett; Jamie Wilhelm; Mi-Ok Kim; George Atweh; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

2.  Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients.

Authors:  Louise Nielsen; Florence Canouï-Poitrine; Jean-Philippe Jais; Djamal Dahmane; Pablo Bartolucci; Bouteina Bentaarit; Justine Gellen-Dautremer; Philippe Remy; Tomek Kofman; Marie Matignon; Caroline Suberbielle; Christian Jacquelinet; Orianne Wagner-Ballon; Dil Sahali; Philippe Lang; Thibaud Damy; Frédéric Galactéros; Philippe Grimbert; Anoosha Habibi; Vincent Audard
Journal:  Br J Haematol       Date:  2016-03-17       Impact factor: 6.998

Review 3.  Renal manifestations of sickle cell disease.

Authors:  V M Buckalew; A Someren
Journal:  Arch Intern Med       Date:  1974-04

4.  Urinary endothelin-1 as a marker of renal damage in sickle cell disease.

Authors:  Pierre-Louis Tharaux; Isabelle Hagège; Sandrine Placier; Michel Vayssairat; Alain Kanfer; Robert Girot; Jean-Claude Dussaule
Journal:  Nephrol Dial Transplant       Date:  2005-09-06       Impact factor: 5.992

5.  Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.

Authors:  Charles T Quinn; Santosh L Saraf; Victor R Gordeuk; Courtney D Fitzhugh; Susan E Creary; Prasad Bodas; Alex George; Ashok B Raj; Alecia C Nero; Catherine E Terrell; Lisa McCord; Adam Lane; Hans C Ackerman; Yu Yang; Omar Niss; Michael D Taylor; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

6.  Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon.

Authors:  Amy Geard; Gift D Pule; Bernard Chetcha Chemegni; Valentina J Ngo Bitoungui; Andre P Kengne; Emile R Chimusa; Ambroise Wonkam
Journal:  Br J Haematol       Date:  2017-05-03       Impact factor: 6.998

7.  Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors.

Authors:  R A Bolarinwa; K S Akinlade; M A O Kuti; O O Olawale; N O Akinola
Journal:  Saudi J Kidney Dis Transpl       Date:  2012-01

8.  Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death.

Authors:  Gregory J Kato; Zeneng Wang; Roberto F Machado; William C Blackwelder; James G Taylor; Stanley L Hazen
Journal:  Br J Haematol       Date:  2008-03-17       Impact factor: 6.998

9.  Renal medullary carcinoma. The seventh sickle cell nephropathy.

Authors:  C J Davis; F K Mostofi; I A Sesterhenn
Journal:  Am J Surg Pathol       Date:  1995-01       Impact factor: 6.394

10.  Morphine promotes renal pathology in sickle mice.

Authors:  Marc L Weber; Derek Vang; Paulo E Velho; Pankaj Gupta; John T Crosson; Robert P Hebbel; Kalpna Gupta
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-07-20
View more
  9 in total

Review 1.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

2.  Oral manifestations of sickle cell disease.

Authors:  M Chekroun; H Chérifi; B Fournier; F Gaultier; I-Y Sitbon; F Côme Ferré; B Gogly
Journal:  Br Dent J       Date:  2019-01-11       Impact factor: 1.626

3.  Renal Abnormalities among Sickle Cell Disease Patients in a Poor Management Setting: A Survey in the Democratic Republic of the Congo.

Authors:  Paul Kambale-Kombi; Roland Marini Djang'eing'a; Jean-Pierre Alworong'a Opara; Jean-Paulin Mbo Mukonkole; Vincent Bours; Serge Tonen-Wolyec; Dieu-Merci Mbumba Lupaka; Lucien Bolukaoto Bome; Charles Kayembe Tshilumba; Salomon Batina-Agasa
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

4.  VEGF Promoter Region 18-bp Insertion-Deletion Polymorphism in Sickle Cell Disease Patients with Microalbuminuria: A Pilot Study.

Authors:  Dnyanesh B Amle; Rachana L Patnayak; Varsha Verma; Gajendra Kumar Singh; Vijaylakshmi Jain; P K Khodiar; P K Patra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-08       Impact factor: 0.900

Review 5.  Sickle cell nephropathy: insights into the pediatric population.

Authors:  Oyindamola C Adebayo; Lambertus P Van den Heuvel; Wasiu A Olowu; Elena N Levtchenko; Veerle Labarque
Journal:  Pediatr Nephrol       Date:  2021-05-29       Impact factor: 3.651

Review 6.  Sickle cell nephropathy: A review of novel biomarkers and their potential roles in early detection of renal involvement.

Authors:  Osama Y Safdar; Rana M Baghdadi; Sereen A Alahmadi; Bana E Fakieh; Amaal M Algaydi
Journal:  World J Clin Pediatr       Date:  2022-01-09

7.  Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study.

Authors:  Franklin Njoku; Xu Zhang; Binal N Shah; Roberto F Machado; Jin Han; Santosh L Saraf; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2021-07-15       Impact factor: 8.615

8.  Atypical presentation of acute post-infectious glomerulonephritis in patients with sickle cell disease: report of two cases.

Authors:  Precil Diego Miranda de Menezes Neves; Bernardo Vergara Reichert; Ramaiane Aparecida Bridi; Luis Yu; Cristiane Bitencourt Dias; Rafaela Brito Bezerra Pinheiro; Leonardo de Abreu Testagrossa; Lívia Barreira Cavalcante; Denise Maria Avancini Costa Malheiros; Lectícia Barbosa Jorge; Viktoria Woronik
Journal:  BMC Nephrol       Date:  2020-02-24       Impact factor: 2.388

9.  Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition.

Authors:  Pamela L Brito; Alisson F Dos Santos; Hanan Chweih; Maria E Favero; Erica M F Gotardo; Juliete A F Silva; Flavia C Leonardo; Carla F Franco-Penteado; Mariana G de Oliveira; Wilson A Ferreira; Bruna C Zaidan; Athanase Billis; Giorgio Baldanzi; Denise A Mashima; Edson Antunes; Sara T Olalla Saad; Fernando F Costa; Nicola Conran
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.